

## Left Ventricular longitudinal Strain before and after Percutaneous Balloon Mitral Valvuloplasty

Ahmed H. E. Arafa<sup>1\*</sup>, Mahmoud K. Ahmed<sup>2</sup>, Ahmed E. A. Soliman<sup>2</sup>

<sup>1</sup>Cardiology Department, Mabarrah Misr Al-Qadema hospital, Cairo, Egypt.

<sup>2</sup>Cardiology Department, Faculty of Medicine, Menoufia University, El Menoufia, Egypt.

\*Corresponding Author: Ahmed H. E. Arafa, Email: [ahmed.helmy.ah955@gmail.com](mailto:ahmed.helmy.ah955@gmail.com), Phone: +201092566072

### ABSTRACT

**Background:** Two-dimensional speckle tracking echocardiography with longitudinal strain analysis is a valuable tool for quantifying left ventricular systolic function in patients with severe mitral stenosis post-percutaneous mitral balloon valvotomy, the established standard treatment for symptomatic severe MS with favorable valve morphology.

**Objectives:** This study aimed to assess left ventricular function before and after percutaneous balloon mitral commissurotomy by using 2D speckle tracking echocardiography.

**Patients and methods:** This was a prospective study that was carried out on 30 patients with severe mitral stenosis undergoing trans-catheter mitral valve commissurotomy using Inoue balloon. Measurement of left ventricular function was performed before and 30 days after PMBV by conventional and two-dimensional strain echocardiography (global longitudinal peak systolic strain).

**Results:** Comparing differences in measurements before and 30 days after balloon mitral valvuloplasty, there were significant improvement in left ventricle (LV) systolic functions according to EF and LV dimensions. As regards longitudinal strain results, there was significant improvement in global longitudinal strain, LVAP2 chamber, LVAP3 chamber and LVAP4 chamber strains. The longitudinal strain of all heart walls showed significant improvement except the inferior wall showed non-significant changes.

**Conclusion:** 2D strain echocardiography revealed enhanced LV systolic function parameters in patients with severe MS following successful PMBV.

**Keywords:** Left ventricular function, Mitral stenosis, Percutaneous mitral balloon, Two-dimensional speckle tracking echocardiography, Valvuloplasty.

### INTRODUCTION

Mitral stenosis (MS) remains a widespread valvular heart disease globally, particularly prevalent in regions with high rates of rheumatic fever, especially in underdeveloped countries <sup>(1)</sup>.

Treatment for symptomatic patients with moderate to severe MS aims to alleviate the mechanical obstruction caused by the stenosis. This can be achieved through percutaneous mitral balloon valvotomy (PMBV) or surgical intervention on the mitral valve <sup>(2)</sup>. PMBV is widely recognized as the standard treatment for individuals with symptomatic severe mitral stenosis and favorable valve morphology <sup>(3)</sup>. Patient selection for PMBV relies on a quantitative scoring system that assesses valve characteristics and commissural calcification <sup>(4, 5)</sup>.

Numerous studies have explored the immediate and long-term outcomes following PMBV <sup>(6)</sup>. This study aimed to evaluate the impact of successful PMBV on left ventricular systolic function, as measured by strain echocardiography, in patients with severe MS.

### PATIENTS AND METHODS

The study included 30 patients with severe mitral stenosis who were admitted to Mabarrah Misr Al-Qadema hospital (Cairo, Egypt) and Menoufia University Hospital to undergo trans-catheter mitral valve commissurotomy at the period from 1st of August 2023 to 31th of July 2024.

**Exclusion criteria:** Patients with severe mitral valve calcification and moderate and severe mitral regurgitation were excluded.

Transthoracic echocardiographic examination was done by Philips IE 30 (Philips Medical Systems, USA) machine and balloon mitral valvotomy (BMV) was planned according to echo findings, speckle tracking echocardiography was done and repeated 30 days after the procedure. All examinations were recorded for offline analysis. Images were imported into a Q-lab software for analysis of global longitudinal strain (GLS) of the myocardium from the average of 17 segments.

**Ethical approval:** Informed consent was taken from each patient after been informed about the procedures and its possible complication. Approval was obtained from The Ethical Committee of Scientific Research of Faculty of Medicine, Menoufia University under code no. (6/2021CARD32). This work had been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans.

### Statistical analysis

The Statistical Package for the Social Sciences (SPSS) version 28 (IBM Corp., Armonk, NY, USA) program was used and data was summarized as mean and standard deviation (SD) for normally distributed variables using the paired sample t-test. A p-value was considered statistically significant if  $\leq 0.05$ .

**RESULTS**

This study included 30 patients diagnosed with severe mitral stenosis and mitral valve area (MVA)  $\leq 1.5$  cm<sup>2</sup> (Wilkins score  $8 \pm 1$ ). The patients were assessed by Two- dimension echocardiography and speckle tracking and were followed-up 1 month after percutan

eous balloon mitral valvuloplasty using single balloon technique with Inoue balloon size (26 – 28 mm). Patients included in this study aged from 27 to 45 years with a mean  $39 \pm 9$  years. Males were 5 (16.7%) and females were 25 (83.3%). A

ccording to the recorded risk factors, 1 patient had DM (3.3%), 5 patients were hypertensive (16.7 %), 4 patients were smokers (13.3%) and 5 patients were recorded dyslipidemic (16.7%). The average blood

pressure of the participants was recorded  $124 \pm 13 / 79 \pm 8$  and their heart rhythm was recorded sinus rhythm in 20 patients (66.7%) and atrial fibrillation in 10 patients (33.35%).

None of the participants had concomitant aortic stenosis, 6 patients (20%) had mild aortic regurgitation. About half of patients had mild to moderate tricuspid regurgitation. Also, 14 patients (46.7%) had mild pulmonary regurgitation and 6 patients (20%) had moderate pulmonary regurgitation, while 10 patients (33%) were free of pulmonary regurgitation. 9 (30%) patients developed grade I/IV MR post-commissurotomy, seven (23.33%) patients developed grade II/IV MR after BMVP (Table 1).

**Table (1):** Demographic characteristics and valvular lesions of the participants

		N (total 30)	%
<b>Gender</b>	<b>Male</b>	5	16.7%
	<b>Female</b>	25	83.3%
<b>Age (Mean <math>\pm</math> SD)</b>		$39 \pm 9$	
<b>DM</b>		1	3.3%
<b>HTN</b>		5	16.7%
<b>Smoking</b>		4	13.3%
<b>Average systolic blood pressure</b>		$124 \pm 13$	
<b>Average diastolic blood pressure</b>		$79 \pm 8$	
<b>Rhythm</b>	<b>Sinus</b>	20	66.7%
	<b>AF</b>	10	33.3%
<b>Valvular lesions rather than mitral stenosis</b>			
		<b>N</b>	<b>%</b>
<b>Aortic valve stenosis</b>		No	30
			100%
<b>Aortic valve regurgitation</b>		No	23
		Mild	6
		Moderate	1
			76.7%
			20%
			3.3%
<b>Tricuspid valve regurgitation</b>		No	4
		Mild	17
		Moderate	9
			13.3%
			56.7%
			30%
<b>Pulmonary valve stenosis</b>		No	27
		Mild	3
			90 %
			10%
<b>Pulmonary valve regurgitation</b>		No	10
		Mild	14
		Moderate	6
			33.3%
			46.7%
			20%
<b>Mitral valve regurgitation grade before and 30 days after balloon mitral valvuloplasty</b>			
<b>Mitral valve regurgitation grade before BMV</b>		No	20
		grade ¼	10
			66.7%
			33.3%
<b>Mitral valve regurgitation grade after BMV</b>		No	14
		grade ¼	9
		grade 2/4	7
			46.67%
			30 %
			23.33%

Data are presented as frequency (%), **BMV**: balloon mitral valvuloplasty. Data are presented as mean  $\pm$  Standard Deviation, **DM**: Diabetes Mellitus; **HTN**: Hypertension; **RHD**: Rheumatic Heart Disease; **AF**: Atrial Fibrillation; **SD**: Standard Deviation.

Echocardiographic findings showed that LV end-diastolic dimensions (LVEDD), end-diastolic volume (EDV), mitral valve area and EF by M mode (pre- $61 \pm 7\%$  - post  $64 \pm 7\%$ ) were significantly increased 30 days after BMVP, while LV end-systolic dimensions (LVESD), end systolic volume (EDV), left atrial diameter, mean pressure gradient (MPG), maximum pressure gradient across mitral valve and the estimated RV end-systolic pressure (ERVSP) were significantly decreased 30 days after BMVP (Table 2 and figures 1 & 2).

**Table (2):** Conventional echocardiographic findings, mitral valve gradients and area of patients before and 30 days after percutaneous balloon valvuloplasty.

	Pre-operative		Post-operative		P-value
	Mean ± SD		Mean ± SD		
<b>LVEDD (mm)</b>	45.00 ± 0.92		47.57 ± 0.83		<0.001*
<b>LVESD (mm)</b>	32.5 ± 13.5		30.77 ± 0.82		0.001*
<b>EDV (MM-Teich) (ml)</b>	105.57 ± 4.7		109.13 ± 4.85		0.029*
<b>ESV (MM-Teich) (ml)</b>	44.23 ± 2.69		40.23 ± 2.58		0.002*
<b>LVPW<sub>s</sub> (mm)</b>	13.8 ± 2.27		13.9 ± 1.3		0.09
<b>LVPW<sub>d</sub> (mm)</b>	9.1 ± 1.65		9.87 ± 1.36		0.35
<b>IVS<sub>s</sub> (mm)</b>	12.1 ± 1.67		13 ± 1.76		0.21
<b>IVS<sub>d</sub> (mm)</b>	8.83 ± 1.51		9.83 ± 1.51		0.76
<b>Aortic Diameter (mm)</b>	23.8 ± 4.8		24.53 ± 4.66		0.061
<b>LA Diameter (mm)</b>	47.6 ± 4.96		41.27 ± 3.61		<0.001*
<b>EF M-mode</b>	0.61 ± 0.07		0.64 ± 0.07		<0.001*
<b>RVESP (mmHg)</b>	52.8 ± 9.17		43.63 ± 6.99		<0.001*
<b>MAX Gradient across MV (mmHg)</b>	26.43 ± 7.44		16.9 ± 4.84		<0.001*
<b>MEAN Gradient across MV (mmHg)</b>	14.6 ± 4.35		7 ± 1.72		<0.001*
<b>MVA planimetry (cm<sup>2</sup>)</b>	1.11±0.15		1.84±0.15		<0.001*

Data are presented as mean ± Standard Deviation, \*: Significant p value ≤0.05. **EDV**: end-diastolic volume. **ESV**: end-systolic volume. **EF**: Ejection fraction. **IVS<sub>d</sub>**: Inter-ventricular septum in diastole. **IVS<sub>s</sub>**: Inter-ventricular septum in systole. **LA**: Left atrium. **LVPW<sub>d</sub>**: Left ventricle posterior wall in diastole. **LVPW<sub>s</sub>**: Left ventricle posterior wall in systole. **LVESD**: Left ventricle end-systolic diameter. **LVEDD**: Left ventricle end- diastolic diameter. **MV**: mitral valve. **RVESP**: right ventricular end-systolic artery pressure.

As regards longitudinal strain results, there was significant improvement in the global longitudinal strain (p=0.03), LVAP2 chamber (p=0.002), LVAP3 chamber (p=0.009) and LVAP4 chamber (p=0.01) strains 30 days after PMBV. The longitudinal strain of LV lateral, septal, anterior, anteroseptal and inferolateral walls showed significant improvement while the inferior wall showed non-significant improvement (p=0.59) (Table 3 and figures 3 & 4).

**Table (3):** Longitudinal LV strain values pre and post balloon mitral valvuloplasty

	Pre-operative		Post-operative		P-value
	Mean	SD	Mean	SD	
<b>LV global longitudinal Strain (%)</b>	18	3	20	3	0.03
<b>LV AP2 chamber strain (%)</b>	18	5	20	4	0.002
<b>Anterior wall strain (%)</b>	16	10	23	10	<0.001
<b>Inferior wall strain (%)</b>	19	8	18	7	0.59
<b>LV AP3 chamber strain (%)</b>	17	8	22	6	0.009
<b>ANT-SEP wall strain (%)</b>	14	5	19	2.3	0.02
<b>INF-LAT wall strain (%)</b>	13	12	20	15	0.02
<b>LV AP4 chamber strain (%)</b>	18	4	23	8	0.01
<b>Lateral wall strain (%)</b>	15	10	21	9	0.04
<b>Septal wall strain (%)</b>	14	4	18	2	0.03

Data are presented as mean ± Standard Deviation, \*: Significant p value ≤0.05, **LVAP**: left ventricular apical projection.




Figure (1): Pre PMVB case 1.




Figure (2): Post P.MBV case 1.




Figure (3): Pre PMBV case 2.




Figure (4): Post PMBV case 2.

## DISCUSSION

Mitral stenosis (MS) is a chronic rheumatic heart valve disease that often leads to pulmonary hypertension but rarely results in left ventricular (LV) systolic dysfunction (7).

Conventional echocardiography parameters measured before and 30 days after balloon mitral valvuloplasty (BMV) demonstrated significant increases in LVEDD, EDV, MVA, and EF, while significant decreases were observed in LVESD, ESV, left atrial diameter, MPG, and EPASP.

Our findings align with **Esteves et al.** (8), who reported significant increases in LVEF, LV end-diastolic volume, and stroke volume following BMV. Similarly, **Pamir et al.** (9) did not observe acute changes in EF after BMV, which is consistent with our findings.

Longitudinal strain echocardiography revealed improved LV function post-BMV, likely due to increased preload, reduced afterload, decreased pulmonary artery pressure, and improved interventricular septum movement.

Increases in LVAP2, LVAP3, and LVAP4 chamber strains were observed in all walls except the inferior wall, which is consistent with the findings of **Bektas et al.** (10), **Sengupta et al.** (11), and **Barros-Gomes et al.** (12). Furthermore, our results align with **Samaan et al.** (13), who noted improvements in LV deformation and ejection fraction after BMV, suggesting reversible myocardial dysfunction.

The absence of improvement in the inferior wall is consistent with **Galli et al.** (14), who reported motion abnormalities in the postero-basal wall in MS patients, potentially due to a tethering effect from the rigid mitral valve apparatus.

As proposed by **Klein et al.** (15), acute rheumatic fever can lead to delayed mitral stenosis, and the inflammatory process can cause fibrosis in heart layers. **Waller et al.** (16) found Aschoff bodies in excised stenotic mitral valves, suggesting myocardial fibrosis. This fibrosis can extend to the myocardium, affecting strain echocardiography results in MS patients compared to the general population, as explained by **Ozdemir et al.** (17),

**Leitman and Vered** (18), and **Roushdy et al.** (19). Alternatively, image quality issues may contribute to tracking inaccuracies (20).

## CONCLUSIONS

A significant improvement in LV systolic function was observed post-PMBV in patients with severe MS, as assessed by 2D strain echocardiography.

## LIMITATIONS

In this study, we faced a limited number of cases, the dependence of echocardiographic speckle tracking on high-quality images, and that the patients included in our study represented only one category of mitral stenosis patients.

**Conflict of interest:** no conflict of interest.

**Funds:** no funds.

## REFERENCES

1. **Marijon E, Mirabel M, Celermajer D et al. (2012):** Rheumatic heart disease. *Lancet*, 379 (9819): 953–964. [https://doi.org/10.1016/S0140-6736\(11\)61171-9](https://doi.org/10.1016/S0140-6736(11)61171-9).
2. **Carabello B (2005):** Modern management of mitral stenosis. *Circulation*, 112 (3): 432–437. <https://doi.org/10.1161/CIRCULATIONAHA.104.532498>.
3. **Nishimura R, Otto C, Bonow R et al. (2014):** 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, 63 (22): e57–e185. <https://doi.org/10.1016/j.jacc.2014.02.536>.
4. **Wilkins G, Weyman A, Abascal V et al. (1988):** Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. *British Heart Journal*, 60 (4): 299–308. <https://doi.org/10.1136/hrt.60.4.299>.
5. **Cannan C, Nishimura R, Reeder G et al. (1997):** **Echocardiographic** assessment of commissural calcium: a simple predictor of outcome after percutaneous mitral balloon valvotomy. *Journal of the American College of*

- Cardiology, 29 (1): 175–180. [https://doi.org/10.1016/s0735-1097\(96\)00422-6](https://doi.org/10.1016/s0735-1097(96)00422-6).
6. **Nunes M, Tan T, Elmariah S *et al.* (2014):** The echo score revisited: Impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. *Circulation*, 129 (8): 886–895. <https://doi.org/10.1161/CIRCULATIONAHA.113.001252>.
  7. **Heller S, Carleton R (1970):** Abnormal left ventricular contraction in patients with mitral stenosis. *Circulation*, 42 (6): 1099–1110. <https://doi.org/10.1161/01.cir.42.6.1099>.
  8. **Esteves W, Lodi-Junqueira L, Soares J *et al.* (2017):** Impact of percutaneous mitral valvuloplasty on left ventricular function in patients with mitral stenosis assessed by 3D echocardiography. *International Journal of Cardiology*, 248: 280–285. <https://doi.org/10.1016/j.ijcard.2017.06.078>.
  9. **Pamir G, Ertaş F, Oral D *et al.* (1997):** Left ventricular filling and ejection fraction after successful percutaneous balloon mitral valvuloplasty. *International Journal of Cardiology*, 59 (3): 243–246. [https://doi.org/10.1016/s0167-5273\(97\)02959-8](https://doi.org/10.1016/s0167-5273(97)02959-8).
  10. **Bektaş O, Günaydin Z, Karagöz A *et al.* (2015):** Evaluation of the effect of percutaneous mitral balloon valvuloplasty on left ventricular systolic function via strain and strain rate in patients with isolated rheumatic mitral stenosis. *The Journal of Heart Valve Disease*, 24 (2): 204–209.
  11. **Sengupta S, Amaki M, Bansal M *et al.* (2014):** Effects of percutaneous balloon mitral valvuloplasty on left ventricular deformation in patients with isolated severe mitral stenosis: a speckle-tracking strain echocardiographic study. *Journal of the American Society of Echocardiography*, 27 (6): 639–647. <https://doi.org/10.1016/j.echo.2014.01.024>.
  12. **Barros-Gomes S, Eleid M, Dahl J *et al.* (2017):** Predicting outcomes after percutaneous mitral balloon valvotomy: the impact of left ventricular strain imaging. *European Heart Journal: Cardiovascular Imaging*, 18 (7): 763–771. <https://doi.org/10.1093/ehjci/jew160>.
  13. **Samaan A, Said K, Aroussy W *et al.* (2021):** Left Ventricular Remodeling Following Balloon Mitral Valvuloplasty in Rheumatic Mitral Stenosis: Magnetic Resonance Imaging Study. *Frontiers in Cardiovascular Medicine*, <https://doi.org/10.3389/fcvm.2021.674435>.
  14. **Galli E, Lancellotti P, Sengupta P *et al.* (2014):** LV mechanics in mitral and aortic valve diseases: value of functional assessment beyond ejection fraction. *JACC: Cardiovascular Imaging*, 7 (11): 1151–1166. <https://doi.org/10.1016/j.jcmg.2014.07.015>.
  15. **Klein A, Carroll J (2006):** Left ventricular dysfunction and mitral stenosis. *Heart Failure Clinics*, 2 (4): 443–452. <https://doi.org/10.1016/j.hfc.2006.09.006>.
  16. **Waller B, Howard J, Fess S (1994):** Pathology of mitral valve stenosis and pure mitral regurgitation - Part I. *Clinical Cardiology*, 17 (6): 330–336. <https://doi.org/10.1002/clc.4960170611>.
  17. **Ozdemir A, Kaya C, Ozcan O *et al.* (2010):** Prediction of subclinical left ventricular dysfunction with longitudinal two-dimensional strain and strain rate imaging in patients with mitral stenosis. *International Journal of Cardiovascular Imaging*, 26 (4): 397–404. <https://doi.org/10.1007/s10554-009-9550-2>.
  18. **Leitman M, Vered Z (2016):** Speckle-tracking imaging for the progression of mitral stenosis. *Anatolian Journal of Cardiology*, 16 (10): 778. <https://doi.org/10.14744/AnatolJCardiol.2016.20172>.
  19. **Roushdy A, Raafat S, Shams K *et al.* (2016):** Immediate and short-term effect of balloon mitral valvuloplasty on global and regional biventricular function: a two-dimensional strain echocardiographic study. *European Heart Journal: Cardiovascular Imaging*, 17 (3): 316–325. <https://doi.org/10.1093/ehjci/jev157>.
  20. **Mehrabi-Pari S, Nayebirad S, Shafiee A *et al.* (2023):** Segmental and global longitudinal strain measurement by 2-dimensional speckle tracking echocardiography in severe rheumatic mitral stenosis. *BMC Cardiovascular Disorders*, 23 (1): 584. <https://doi.org/10.1186/s12872-023-03624-x>.